Preventive Treatment Of Migra... Health Article

References

1 Silberstein S.D.. Headache in Clinical Practice 2nd edn 2002 Taylor & Francis
2 Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders (2nd edn). Cephalalgia 24 (Suppl. 1), 1–160
3 Silberstein S.D.. Migraine preventive medication reduces resource utilization Headache 43 2003 171 178
4 Ramadan N.M.. Evidenced-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine Neurology 2000
5 Lipton R.B.. Migraine in the United States: epidemiology and patterns of health care use Neurology 58 2002 885 894
6 Olesen J.. Timing and topography of cerebral blood flow, aura and headache during migraine attacks Ann. Neurol. 28 1990 791 798
7 Pietrobon D., Striessnic J.. Neurobiology of migraine Nat. Rev. Neurosci. 4 2003 386 398
8 Goadsby P.J.. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann. Neurol. 28 1990 183 187
9 Dimitriadou V.. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat aura mater and tongue following antidromic trigeminal stimulation Neuroscience 48 1992 187 203
10 Burstein R., Jakubowski M.. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization Ann. Neurol. 55 2004 27 36
11 Kandere-Grzybowska K.. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice Brain Res. 980 2003 213 220
12 Oshinsky, M. and Luo, J. (2006) Neurochemistry of a rat migraine model. Headache (in press)
13 Ayata C.. Suppression of cortical spreading depression in migraine prophylaxis Ann. Neurol. 59 2006 652 661
14 Theis M.. Emerging complexities in identity and function of glial connexins Trends Neurosci. 28 2005 188 195
15 Goadsby P.J.. Can we develop neurally acting drugs for the treatment of migraine? Nat. Rev. Drug Discov. 4 2005 741 750
16 Silberstein S.D., Goadsby P.J.. Migraine: preventive treatment Cephalalgia 22 2002 491 512
17 Gray R.N.. Drug treatments for the prevention of migraine headache. Prepared for the Agency for Health Care Policy and Research, contract 290-94-2025 National Technical Information Service 1999
18 Linde K., Rossnagel K.. Propranolol for migraine prophylaxis Cochrane Database Syst. Rev. 2004
19 Ozyalcin S.N.. The efficacy and safety of venlafaxine in the prophylaxis of migraine Headache 45 2005 144 152
20 Ophoff R.A.. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca channel gene Cell 87 1996 543 552
21 Coulam C.B., Annagers J.R.. New anticonvulsants reduce the efficacy of oral contraception Epilepsia 20 1979 519 525
22 Hansten P.D., Horn J.R.. Drug Interaction Newsletter 5 1985 7 10
23 Silberstein S.D.. Topiramate in migraine prevention Headache 45 2005 S57 S65
24 Easterling D.E.. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans Epilepsia 29 1988 662
25 MacDonald R.L., McLean M.J.. Anticonvulsant drugs: mechanisms of action A.D. Escueta Advances in Neurology 1986 Raven Press 713 736
26 Shank R.P.. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action Epilepsia 41 2000 S3 S9
27 Rogawski M.A., Porter R.J.. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds Pharmacol. Rev. 42 1990 223 286
28 Dodgson S.J.. Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia 41 2000 S35 S39
29 DeLorenzo R.J.. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons Epilepsia 41 2000 S40 S44
30 Zona C.. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells Neurosci. Lett. 231 1997 123 126
31 Krebs E.G.. The growth of research on protein phosphorylation Trends Biochem. Sci. 19 1994 439
32 Roche K.W.. Characterization of multiple phosphorylation sites on the AMP receptor GluR1 subunit Neuron 16 1996 1179 1188
33 Wang J.H., Kelly P.T.. Postsynaptic injection of CA/CaM induces synaptic potentiation requiring CaMKII and PKC activity Neuron 15 1995 443 452
34 Sigel E.. Functional modulation of ligand-gated GABA and NMDA receptor channels by phosphorylation J. Recept. Signal Transduct. Res. 15 1995 325 332
35 Storer R.J., Goadsby P.J.. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine Neurology 60 2003 A238
36 Silberstein S.D.. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study Arch. Neurol. 61 2004 490 495
37 Brandes J.L.. Topiramate for migraine prevention: a randomized controlled trial JAMA 291 2004 965 973
38 Diener H.C.. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control J. Neurol. 251 2004 943 950
39 Sachdeo R.C.. Topiramate monotherapy for partial onset seizures Epilepsia 38 1997 294 300
40 Thomson Healthcare null. Physicians’ Desk Reference 59th edn 2005 Thomson Healthcare
41 Greenwood R.S.. Adverse effects of antiepileptic drugs Epilepsia 41 2000 S42 S51
42 York D.A.. Effect of topiramate on body weight and body composition of Osborne–Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs Nutrition 16 2000 967 975
43 Richard D.. Influence of topiramate in the regulation of energy balance Nutrition 16 2000 961 966
44 Löscher W.. Valproic acid: mechanisms of action R.H. Levy Antiepileptic Drugs 5th edn 2002 Lippincott Williams & Wilkins 767 779
45 McNamara J.O.. Drugs effective in the therapy of the epilepsies J.G. Hardman Goodman's and Gilman's the Pharmacological Basis of Therapeutics 10th edn 2001 McGraw-Hill 521 548
46 Silberstein S.D.. Valproic acid: clinical efficacy and use in other neurological disorderss R.H. Levy Antiepileptic Drugs 5th edn 2002 Lippincott Williams & Wilkins 818 827
47 Rimmer E.M., Richens A.. An update on sodium valproate Pharmacotherapy 5 1985 171 184
48 Chapman A.. Mechanisms of anticonvulsant action of valproate Prog. Neurobiol. 19 1982 315 359
49 Moskowitz M.A.. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine Trends Pharmacol. Sci. 13 1992 307 311
50 Freitag F.G.. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis Neurology 58 2002 1652 1659
51 Silberstein S.D., Collins S.D.. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study (for the long-term safety of depakote in headache prophylaxis study group) Headache 39 1999 633 643
52 Silberstein S.D.. Divalproex sodium in headache – literature review and clinical guidelines Headache 36 1996 547 555
53 Bayer K.. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca channels Neuropharmacology 46 2004 743 749
54 Rogawski M.A., Loscher W.. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions Nat. Med. 10 2004 685 692
55 Mathew N.T.. Gabapentin in migraine prophylaxis Cephalalgia 16 1996 367
56 Wessely P.. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin Cephalalgia 7 1987 477 478
57 Mathew N.T.. Efficacy of gabapentin in migraine prophylaxis Headache 41 2001 119 128
58 D’Andrea G.. Migraine with aura from pathophysiology to treatment: therapeutic strategies Neurol. Sci. 26 Suppl. 2 2005 S104 S107
59 Wheeler S.D.. Lamotrigine efficacy in migraine prevention Cephalalgia 21 2001 374
60 Steiner T.J.. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura Cephalalgia 17 1997 109 112
61 Lampl C.. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura J. Neurol. Neurosurg. Psychiatry 76 2005 1730 1732
62 Oshinsky M.L.. Botulinum toxin and migraine: how does it work? Practical Neurology Suppl. 2004 10 13
63 Silberstein S.D.. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group Headache 40 2000 445 450
64 Dodick D.W.. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study Headache 45 2005 315 324
65 Silberstein S.D.. Migraine Lancet 363 2004 381 391
66 Silberstein S.D.. Migraine: diagnosis and treatment S.D. Silberstein Wolff's Headache and Other Head Pain 7th edn 2001 Oxford University Press 121 237